[Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options].
作者： C.G. Hammerschmied , B. Walter , A. Hartmann
DOI: 10.1007/S00292-008-1011-5
关键词:
摘要: By integrating genetic data into the traditional histology and immunohistochemistry-based classification system revised WHO-classification of malignant tumours (2004) defined additional renal cell carcinoma subtypes, thereby enabling application diagnostic procedures. Therapy for advanced clear has also seen significant progress. This report focuses on these developments, pinpoints current obstacles provides future prospects.
springer.com
sci-hub.se 参考文章(43)
K. Junker, F. von Eggeling, J. Müller, T. Steiner, J. Schubert, Identifizierung von Biomarkern und therapeutischen Targets beim Nierenzellkarzinom mittels ProteinChip-Technologie Urologe A. ,vol. 45, pp. 305- 315 ,(2006) , 10.1007/S00120-006-1001-2
TNM classification of malignant tumours Published in <b>2010</b> in Chichester, West Sussex, UK ;Hoboken, NJ by Wiley-Blackwell. ,(1987) , 10.1007/978-3-642-82982-6
John N. Eble, Pathology and genetics of tumours of the urinary system and male genital organs IARC Press. ,(2004)
Brett Delahunt, Peter B. Bethwaite, John N. Nacey, Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype Pathology. ,vol. 39, pp. 459- 465 ,(2007) , 10.1080/00313020701570061
Sylvie Negrier, David Perol, Alain Ravaud, Christine Chevreau, Jacques-Olivier Bay, Remy Delva, Emmanuel Sevin, Armelle Caty, Bernard Escudier, , Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. ,vol. 110, pp. 2448- 2457 ,(2007) , 10.1002/CNCR.23056
Eric C. Nelson, Christopher P. Evans, Primo N. Lara, Renal cell carcinoma : Current status and emerging therapies Cancer Treatment Reviews. ,vol. 33, pp. 299- 313 ,(2007) , 10.1016/J.CTRV.2006.12.005
Heiko Wunderlich, Winfried Hindermann, Al Mohannad Al Mustafa, Olaf Reichelt, Kerstin Junker, JÖRG SCHUBERT, None, THE ACCURACY OF 250 FINE NEEDLE BIOPSIES OF RENAL TUMORS The Journal of Urology. ,vol. 174, pp. 44- 46 ,(2005) , 10.1097/01.JU.0000162063.86400.DE
James C. Yang, Bevacizumab for Patients with Metastatic Renal Cancer: Fig. 1. Clinical Cancer Research. ,vol. 10, pp. 6367S- 6370S ,(2004) , 10.1158/1078-0432.CCR-050006
David J. Kwiatkowski, Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biology & Therapy. ,vol. 2, pp. 471- 476 ,(2003) , 10.4161/CBT.2.5.446
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655